Switching from Tirzepatide to Retatrutide: What Researchers Should Know

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

Why Researchers Consider Switching

Tirzepatide has been a breakthrough. In clinical trials, it helped people lose an average of 20.2% of their body weight over 72 weeks. That is a big deal. But some researchers are now looking at something even more powerful: retatrutide.

Why? Because retatrutide hit 24.2% weight loss in its phase 2 trial. That is roughly 4 percentage points more than tirzepatide — and it does something tirzepatide cannot do at all. It activates a third receptor.

If you have been studying tirzepatide and hit a plateau — or you simply want to understand the next step in this research — this guide breaks it all down in plain language.

The Big Difference: Two Receptors vs. Three

Think of receptors like switches in the body. Each one controls different things.

Tirzepatide flips two switches:

• GLP-1 — makes you feel full, slows digestion, helps control blood sugar
• GIP — boosts insulin, affects how the body stores and burns fat

Retatrutide flips those same two switches plus a third one:

• GLP-1 — same appetite and blood sugar effects
• GIP — same fat and insulin effects
• Glucagon receptor — this is the game changer. It tells the body to burn stored energy, especially fat in the liver. It also raises the body’s resting calorie burn.

That third switch is why researchers are so excited. The glucagon receptor does not just reduce how much you eat. It actually makes the body burn more fuel, even at rest. That is a completely different approach to fat loss.

What the Clinical Data Shows

Tirzepatide Results

The SURMOUNT-1 trial tested tirzepatide at doses of 5 mg, 10 mg, and 15 mg. At the highest dose, people lost an average of 22.5% of their body weight over 72 weeks. That is roughly 52 pounds for someone starting at 230 lbs.

In the SURMOUNT-5 head-to-head trial against semaglutide, tirzepatide showed 20.2% weight loss compared to semaglutide’s 13.7%. It was clearly the stronger compound.

Retatrutide Results

The phase 2 trial tested retatrutide at doses of 1 mg, 4 mg, 8 mg, and 12 mg. At the 12 mg dose over 48 weeks:

• 24.2% average body weight loss
• More than 90% of participants lost at least 10% of their body weight
• Nearly two-thirds lost 20% or more
• A quarter of participants lost 30% or more

Those numbers are remarkable. And the trial was only 48 weeks long — shorter than tirzepatide’s 72-week SURMOUNT trials. Some researchers believe the results would be even larger with a longer study period.

The Liver Fat Advantage

Here is something tirzepatide simply cannot match. In a separate phase 2a trial focused on fatty liver disease (called MASLD), retatrutide reduced liver fat by up to 82% at the 12 mg dose. At 48 weeks, 93% of people on the 12 mg dose had normal liver fat levels.

This matters because fatty liver affects roughly 30% of adults worldwide. Tirzepatide does reduce liver fat to some degree, but the glucagon receptor activation in retatrutide appears to target liver fat directly and aggressively.

Side-by-Side Comparison

Feature	Tirzepatide	Retatrutide
Type	Dual agonist (GLP-1 + GIP)	Triple agonist (GLP-1 + GIP + Glucagon)
Peak Weight Loss	22.5% (72 weeks)	24.2% (48 weeks)
Liver Fat Reduction	Moderate	Up to 82%
Dosing Frequency	Once weekly	Once weekly
Dose Range	5 mg, 10 mg, 15 mg	1 mg, 4 mg, 8 mg, 12 mg
GI Side Effects	Common (nausea, diarrhea)	Slightly higher rates
Approval Status	FDA-approved (Mounjaro/Zepbound)	Phase 3 trials ongoing
Calorie Burn Effect	Minimal	Increased resting energy expenditure

Practical Considerations for Researchers

Dosing Differences

Both compounds are dosed once a week via injection. But the escalation schedules are different.

Tirzepatide typically starts at 2.5 mg and ramps up to a maximum of 15 mg over several weeks. Retatrutide trials started at 0.5 mg and escalated up to 12 mg. Both use a slow ramp-up to let the body adjust and reduce nausea.

The key point: you do not jump from a full dose of tirzepatide straight to a full dose of retatrutide. Any transition protocol in a research setting would involve starting retatrutide at its lowest dose and escalating from there.

Side Effect Profiles

Both peptides cause similar side effects. The most common ones are gut-related:

• Nausea (most common, usually worst during dose escalation)
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite (which is partly the point)

Research data suggests retatrutide has slightly higher rates of these GI side effects compared to tirzepatide, likely because of the added glucagon receptor activation. However, most side effects are mild to moderate and tend to settle down once the body adjusts to the maintenance dose.

Interestingly, in the SURMOUNT-5 head-to-head trial, more people dropped out due to GI side effects on semaglutide (5.6%) than on tirzepatide (2.7%). This suggests tirzepatide may actually be easier on the stomach than some alternatives.

Transition Timing

There is no published clinical protocol for switching directly from tirzepatide to retatrutide. In research settings, the standard approach is:

1. Complete the current tirzepatide research protocol
2. Allow a washout period (the half-life of tirzepatide is about 5 days, so researchers typically wait 2-4 weeks)
3. Begin retatrutide at the lowest dose and escalate according to the trial protocol

What Researchers Are Actually Reporting

The research community is paying close attention to retatrutide for three reasons:

1. The weight loss numbers are higher. Even in a shorter trial, retatrutide outperformed tirzepatide. Phase 3 data will tell us if that advantage holds up in larger, longer studies.

2. The liver fat data is unprecedented. No other GLP-1 based compound has shown an 82% reduction in liver fat. For researchers studying metabolic disease, this is a potential breakthrough.

3. The mechanism is fundamentally different. Adding glucagon receptor activation is not just “more of the same.” It changes how the body handles energy. Instead of just eating less, the body burns more. That is a qualitatively different approach.

However, researchers also note important caveats. Retatrutide is still in phase 3 trials. The phase 2 data is promising but involved fewer participants than the large SURMOUNT program. Long-term safety data beyond 48 weeks is still being collected.

Where to Source Research-Grade Peptides

NorthPeptide carries both retatrutide and tirzepatide in research-grade purity (99%+), verified by HPLC testing with a Certificate of Analysis included with every order. We also carry semaglutide for comparison studies, plus essential supplies like bacteriostatic water.

Every order is backed by our purity, customs, and arrival guarantees.

Summary of Key Research References

Study	Year	Key Finding
Jastreboff et al., NEJM — Retatrutide Phase 2 (PMID: 37366315)	2023	Retatrutide 12 mg achieved 24.2% body weight loss at 48 weeks in adults with obesity
Jastreboff et al., NEJM — SURMOUNT-1 (PMID: 35658024)	2022	Tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks
Hartman et al., Nature Medicine — Retatrutide MASLD Trial (PMC11271400)	2024	Retatrutide 12 mg reduced liver fat by 82.4%; 93% of subjects achieved normal liver fat at 48 weeks
Lilly — SURMOUNT-5 Head-to-Head (PMID: 40353578)	2025	Tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks
Network Meta-Analysis — Retatrutide vs Tirzepatide (PMC12544991)	2025	Retatrutide showed greater absolute weight reduction (-16.34 kg) vs tirzepatide (-11.82 kg)
Borner et al. — GLP-1 RA GI Adverse Events (PMC9821052)	2023	GI adverse events occur in 40-70% of GLP-1 RA users; usually transient during dose escalation

For laboratory and research use only. Not for human consumption.